Last reviewed · How we verify
VN — Competitive Intelligence Brief
marketed
live, attenuated vaccine
Infectious Disease
Biologic
Live · refreshed every 30 min
Target snapshot
VN (VN) — Biomedical Advanced Research and Development Authority. Venezuelan equine encephalitis virus (VEEV) vaccine is a live, attenuated vaccine that stimulates an immune response against VEEV.
Comparator set (1 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| VN TARGET | VN | Biomedical Advanced Research and Development Authority | marketed | live, attenuated vaccine | ||
| VARIVAX® 2016 Commercial Process | VARIVAX® 2016 Commercial Process | Merck Sharp & Dohme LLC | phase 3 | Live, attenuated vaccine |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (live, attenuated vaccine class)
- Biomedical Advanced Research and Development Authority · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- VN CI watch — RSS
- VN CI watch — Atom
- VN CI watch — JSON
- VN alone — RSS
- Whole live, attenuated vaccine class — RSS
Cite this brief
Drug Landscape (2026). VN — Competitive Intelligence Brief. https://druglandscape.com/ci/vn. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab